Effects of a 12-Week Mediterranean-Type Time-Restricted Feeding Protocol in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial-The 'CHRONO-NAFLD Project'
Tsitsou S, Bali T, Adamantou M, Saridaki A, Poulia KA, Karagiannakis DS, Papakonstantinou E, Cholongitas E
Alimentary pharmacology & therapeutics · 27 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- European Foundation for the Study of Diabetes
- Organización sin fines de lucro
- European Association for the Study of Diabetes
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-02-28 · Aliment Pharmacol Ther · vol. 61 · número 8 · págs. 1290–1309
- Editorial
- Wiley
- Citado
- 36 citas · más que el 100% de estudios similares · 19.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 57 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Dietary Effects on Health · Liver Disease Diagnosis and Treatment · Nutritional Studies and Diet
- Palabras clave
- Mediterranean diet, time-restricted feeding, non-alcoholic fatty liver disease, insulin resistance, hypocaloric diet, obesity, overweight, glycemic control, blood pressure, body weight
- MeSH
- humans, obesity, body mass index, treatment outcome, diet, mediterranean, time factors, adult, middle aged, female, male, overweight, non-alcoholic fatty liver disease, intermittent fasting
8 autores
- Sofia Tsitsou🇬🇷Agricultural University of Athens
- Triada Bali🇬🇷National and Kapodistrian University of Athens; Laiko General Hospital of Athens
- Magdalini Adamantou🇬🇷National and Kapodistrian University of Athens; Laiko General Hospital of Athens
- Aristi Saridaki🇬🇷National and Kapodistrian University of Athens; Laiko General Hospital of Athens
- Kalliopi‐Anna Poulia🇬🇷Agricultural University of Athens
- Dimitrios S. Karagiannakis🇬🇷National and Kapodistrian University of Athens
- Emilia Papakonstantinou🇬🇷 · autor de correspondenciaAgricultural University of Athens
- Εvangelos Cholongitas🇬🇷 · autor de correspondenciaNational and Kapodistrian University of Athens; Laiko General Hospital of Athens
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The Mediterranean diet (MD) is considered the best dietary approach for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Recently, time-restricted feeding (TRF) has gained attention for its lifestyle compatibility and health benefits.
Aims
This study aimed to compare the effects of a hypocaloric MD with a 10-h TRF protocol to an unrestricted MD in MASLD patients with overweight/obesity and evaluate differences between early and late TRF.
Methods
This 12-week randomised controlled trial in MASLD patients with overweight/obesity consisted of three groups, all following a hypocaloric Mediterranean-type diet. The control group had no eating time restrictions. The early TRF (eTRF) and late TRF (lTRF) groups had a 10-h eating window, from 8 AM to 6 PM and from 12 PM to 10 PM, respectively. Various health parameters were measured. Compliance was tracked via food diaries, and an 8-week follow-up occurred post-intervention.
Results
Fifty-nine MASLD individuals (27 males; 52.9 years; body mass index 32.1 kg/m2) completed the trial (control, n = 19; eTRF, n = 20; lTRF, n = 20). All groups showed significant 12-week reductions in body weight, anthropometry and blood pressure. Glycated haemoglobin A1c and insulin resistance, as measured by the Matsuda index, homeostatic model assessment for insulin resistance and fasting glucose-to-insulin ratio, improved in the eTRF group at 12 weeks.
Conclusions
This study corroborates the efficacy of MD in ameliorating cardiometabolic risk factors such as body weight and blood pressure in MASLD patients. The combination with an eTRF protocol may improve glycaemic control (NCT05866744).
Trial registration
The study is registered at clinicaltrials.gov (NCT05866744).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.